Bald Cypress Allergy Shots: Florida's Winter Cupressaceae Allergen
Bald cypress allergy shots (SCIT) address Florida's winter Cupressaceae aeroallergen — the classic wetland tree of the Everglades and Gulf Coast bayous, with a December–February pollen season documented by Bucholtz and Lockey (1985) to produce positive nasal challenges in 71% of sensitized rhinitis subjects. Bald cypress has no IUIS-named allergen, but IgE inhibition cross-reactivity with red cedar is documented, placing it firmly in the Cupressaceae pectate-lyase family for clinical management.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Bald Cypressis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Bald Cypress Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to bald cypress — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of bald cypress allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of bald cypress immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of bald cypress extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for bald cypress allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing bald cypress extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription bald cypress immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat bald cypress allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Bald Cypress?
The biology, taxonomy, and clinical fingerprint of Bald Cypress — the foundation of how SCIT targets it.
Taxodium distichum (bald cypress) in the Florida Everglades releasing pollen December through February. Despite no IUIS-named allergen, the seminal Bucholtz & Lockey 1985 study documented 71% positive nasal challenges in sensitized rhinitis subjects.
- Scientific name
- Taxodium distichum
- Family
- Cupressaceae (formerly Taxodiaceae, reclassified)Cypress family
- Type
- Winter tree pollen
- Native to
- Southeastern US wetlands (Florida, Georgia, Louisiana, Alabama, Mississippi, South Carolina, eastern Texas) and Gulf Coast river bottoms
- Allergen proteins
- No IUIS-named allergen as of 2025 (allergen.org) — WHO/IUIS does not list any Taxodium allergensCross-reactivity with red cedar (Juniperus virginiana) demonstrated by IgE inhibition — Ramirez DA & Lockey RF, Ann Allergy Asthma Immunol 2012Inferred pectate-lyase proteins based on Cupressaceae family chemistry (Jun a 1 / Cup a 1 framework); no molecular characterization beyond IgE inhibition studies
- Particle size
- ~20–25 μm (approximate; consistent with general Cupressaceae morphology)
- Avoidance difficulty
- Very difficult
How Bald Cypress Allergy Presents
Symptoms by body system — useful for distinguishing Bald Cypress sensitivity from overlapping allergies and infections.
Respiratory
- Nasal congestion and rhinorrhea during December–February bald cypress pollen season in Florida and Gulf states
- Sneezing triggered by proximity to bald cypress in parks, swamps, and river corridors
- Asthma exacerbations in sensitized patients during the winter Cupressaceae window
- Chronic cough and postnasal drip across the December–February season
Ocular
- Bilateral allergic conjunctivitis during December–February outdoor exposure in the Southeast
- Periorbital swelling on peak pollen days in Florida and Louisiana
- Persistent eye redness extending through the winter Cupressaceae season
Dermal
- Contact urticaria from handling bald cypress bark or cones
- Generalized skin itching on high-pollen days in sensitized individuals
- Eczema flares in atopic patients during the winter pollen window
Systemic
- Fatigue from sustained December–February allergy burden during Florida's peak tourism season
- Sleep disruption from nocturnal nasal blockage
- Headache from sinus pressure during peak pollen days
- Reduced outdoor enjoyment during Florida's otherwise ideal winter weather
Bald cypress is Florida's December-January cedar fever equivalent. Patients who move from the Texas Hill Country and expect to escape cedar season in Florida often experience the same winter respiratory pattern — because it is the same Cupressaceae protein family chemistry, just a different tree in a different ecosystem. Knowing this helps set realistic expectations for SCIT cross-protection.
When & Where Bald Cypress Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late December through January in Florida; secondary peak in February; parallels mountain cedar season in timing but opposite geography· ~8–10 weeks December–February in Florida; season shifts earlier with warming winters per Anderegg et al. PNAS 2021
US Exposure Map
2 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- None
- WV:
- None
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Low
- SC:
- Moderate
- OK:
- Low
- LA:
- High
- MS:
- Moderate
- AL:
- Moderate
- GA:
- Moderate
- TX:
- Moderate
- FL:
- High
- AK:
- Low
- HI:
- Low
What Bald Cypress Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Bald cypress lacks an IUIS-named allergen, but cross-reactivity by IgE inhibition with red cedar (Juniperus virginiana) has been formally documented by Ramirez and Lockey (2012), establishing its membership in the Cupressaceae pectate-lyase family for clinical management purposes. This places bald cypress SCIT within the established Cupressaceae immunotherapy framework.
IgE inhibition cross-reactivity formally documented — Ramirez DA & Lockey RF, Ann Allergy Asthma Immunol 2012
Same Cupressaceae pectate-lyase family; cross-reactivity inferred via family-level chemistry (Jun a 1 / Cup a 1 framework)
Is SCIT Right for Your Bald Cypress Allergy?
Answer five questions to assess whether bald cypress SCIT is right for your winter allergy profile.
How severe are your December–February allergy symptoms in Florida or Gulf Coast states?
The Bald Cypress SCIT Protocol
Bald cypress SCIT uses Cupressaceae family extracts (red cedar, mountain cedar, or regional Cupressaceae mixes) given that no bald-cypress-specific extract has formal characterization. Cross-reactivity by IgE inhibition (Ramirez & Lockey 2012) supports this family-level approach.
Dose escalation using Cupressaceae family extract (red cedar or regional mix with bald cypress). Build-up begins in summer to reach maintenance before December bald cypress season in Florida. Traditionally each injection was followed by a 30-minute observation period in the clinic; with Curex, eligible patients self-administer the same escalation schedule at home, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand.
Ongoing maintenance injections on a schedule individualized by your allergist sustain Cupressaceae family pectate-lyase tolerance. Cross-protection to bald cypress develops via the IgE inhibition cross-reactivity documented by Ramirez & Lockey 2012. With Curex these maintenance doses are self-administered at home, and a 30-minute self-observation continues throughout, with any changes to a new vial or concentration supervised live in the Virtual Shot Room.
After completing 3–5 years, your allergist assesses durable tolerance. Duration of lasting benefit varies; many patients sustain reduced winter cypress symptoms for years post-SCIT.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Bald Cypress SCIT
Bald cypress SCIT is supported by the seminal Bucholtz & Lockey 1985 nasal challenge data and the Ramirez & Lockey 2012 IgE inhibition cross-reactivity study. No RCT specific to bald cypress exists; the Cupressaceae family evidence base (mountain cedar observational data) cross-applies via IgE inhibition cross-reactivity.
- Positive nasal challenge in sensitized rhinitis subjects71%Bucholtz GA, Lockey RF, Serbousek D. Bald cypress tree pollen as an aeroallergen. Ann Allergy 1985;55:805–810 — 71% nasal challenge positivity (12/17); RAST+ in 59%
- RAST-positive rate in sensitized patients59%Bucholtz GA, Lockey RF, Serbousek D. Ann Allergy 1985;55:805–810 — 59% RAST+ in the sensitized cohort
- IgE inhibition cross-reactivity with red cedar (cross-protection basis)65%Ramirez DA, Lockey RF. Bald cypress as an aeroallergen. Ann Allergy Asthma Immunol 2012;108(1):52–54 — IgE inhibition documents Cupressaceae family cross-reactivity
No randomized controlled trial specific to bald cypress SCIT has been published as of 2025. The seminal Bucholtz & Lockey 1985 data established bald cypress as a true clinical aeroallergen (71% nasal challenge positivity), and Ramirez & Lockey 2012 documented IgE inhibition cross-reactivity with red cedar. The honest evidence summary: bald cypress has NO IUIS-named allergen and no molecular characterization beyond IgE inhibition — SCIT is anchored to Cupressaceae family extracts using the mountain-cedar and red-cedar evidence base, with cross-protection to bald cypress inferred rather than directly demonstrated.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Bald Cypress SCIT Side Effects
Bald cypress SCIT (Cupressaceae family extract) carries the standard inhalant immunotherapy side-effect profile — local reactions are expected during build-up; serious systemic reactions are rare.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Expected wheal and flare; resolves within 30–60 minutes during build-up | Rate 30–50% | Mild |
Injection-site itching Localized pruritus managed with cold compress or pre-injection antihistamine | Rate 25–40% | Mild |
Large local reaction Swelling >5 cm persisting >24 hours; requires dose adjustment per JTF 2023 | Rate 5–10% | Moderate |
Delayed local induration Firm nodule for 1–3 days; resolves spontaneously | Rate 3–8% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or conjunctivitis flare Sneezing or eye watering within 30 minutes post-injection; self-limiting | Rate 1–3% | Mild |
Mild urticaria Generalized hives without systemic compromise; requires dose reduction | Rate 0.5–1% | Moderate |
Mild asthma exacerbation Bronchospasm during build-up; pre-injection spirometry standard for asthmatic patients | Rate 0.1–0.5% | Moderate |
Anaphylaxis Managed immediately with epinephrine; with Curex the first injection from each new vial or concentration is supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector is confirmed on hand, with onset typically within 30 minutes | Rate <0.1% per injection | Severe |
Bald cypress serum is sterile-compounded to USP <797>, and with Curex the first injection from each new vial or concentration is supervised live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand. A 30-minute post-injection self-observation captures the vast majority of systemic reactions (Greenhawt et al., Ann Allergy Asthma Immunol 2023).
SCIT vs Alternatives for Bald Cypress
Florida and Gulf-state patients with bald cypress allergy have four options: SCIT (Cupressaceae family extract via IgE cross-reactivity) — now available as a weekly at-home injection with Curex — sublingual drops, avoidance, or daily antihistamines during December–February.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Cupressaceae family cross-protection via IgE inhibition (Ramirez & Lockey 2012); mountain-cedar evidence base via family-level chemistry | Emerging evidence; Cupressaceae pectate-lyase drops provide family-level immunologic activity | Difficult in Florida wetland and urban environments with widespread bald cypress | Good for mild-moderate Florida winter AR; adequate for most patients |
| 5-yr cost | $3,500–$15,000 over 5 years | Varies by provider; sold as a general sublingual modality, not Curex's product | Low direct cost; moderate lifestyle burden | $300–$1,200/year for prescriptions |
| Duration | 3–5 years; weekly build-up then maintenance on a schedule individualized by your allergist | 3–5 years daily drops | Permanent lifestyle restriction during December–February | Lifelong seasonal use |
| Convenience | At-home weekly self-injection with Curex for ~6 months; the first injection from each new vial or concentration supervised live in the Virtual Shot Room | At-home; no clinic visits needed | HEPA filtration indoors helps; outdoor avoidance in Florida swamp regions impractical | Convenient daily antihistamines and nasal steroids |
| Safety | Excellent; rare systemic reactions with observation | Lower systemic reaction risk than SCIT | No treatment risk; no disease modification | Well-established safety profile |
| Lasting effect | Years of lasting benefit after completing course | Duration of benefit still being studied | No lasting benefit; symptoms return every winter | No lasting benefit; symptoms return when medications stop |
SCITBest
SLIT
Avoidance
Medications
For Florida patients with December–February bald cypress allergy who have failed pharmacotherapy, Cupressaceae SCIT anchored to red cedar or regional cypress extract provides the best-available treatment using IgE inhibition cross-reactivity. Curex's at-home IgE test detects Cupressaceae sensitization even without a bald-cypress-specific component, and Curex now delivers that SCIT as a weekly at-home injection with pricing confirmed in a current program quote — the serum is sterile-compounded to USP <797>, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, and a prescribed epinephrine auto-injector is confirmed on hand — providing Cupressaceae family-level protection via the shared pectate-lyase chemistry (Midoro-Horiuti 1999; Ramirez & Lockey 2012).
What Bald Cypress SCIT Actually Costs
Cupressaceae SCIT for Florida bald cypress sensitization is typically covered under standard allergy benefits when Cupressaceae sensitization is confirmed. Since bald cypress lacks a named allergen, the prescription may be documented as red cedar or regional Cupressaceae SCIT with bald cypress cross-reactivity noted in the clinical record. Out-of-pocket cost depends on your plan's deductible and co-insurance.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your bald cypress allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Bald Cypress SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
No — bald cypress (Taxodium distichum) has no IUIS-named allergen as of 2025 (allergen.org). The WHO/IUIS Allergen Nomenclature Sub-Committee has not formally registered any Taxodium allergens. The primary evidence for bald cypress as an aeroallergen comes from the seminal Bucholtz & Lockey 1985 paper (Ann Allergy 1985;55:805–810) documenting 71% positive nasal challenges and 59% RAST-positivity in sensitized rhinitis subjects, and the Ramirez & Lockey 2012 paper (Ann Allergy Asthma Immunol 2012) documenting IgE inhibition cross-reactivity with red cedar. The absence of a named allergen is a molecular characterization gap — not evidence that bald cypress is non-allergenic.
The symptoms are similar and the protein family is related, but bald cypress and mountain cedar are different plants in different ecosystems. Mountain cedar (Juniperus ashei) in Texas produces the classic 'cedar fever' with counts up to 32,000 grains/m³ and a named allergen Jun a 1. Bald cypress (Taxodium distichum) grows in Florida and Gulf Coast wetlands, also peaks December–February, and produces positive nasal challenges in 71% of sensitized subjects (Bucholtz 1985) — but has no named allergen and lower pollen counts than Texas cedar fever. The Ramirez & Lockey 2012 paper formally documents IgE inhibition cross-reactivity between bald cypress and red cedar, establishing that both belong to the same clinical Cupressaceae immunologic unit.
Bucholtz GA, Lockey RF, and Serbousek D published 'Bald cypress tree pollen as an aeroallergen' in the Annals of Allergy in 1985. This is the foundational paper establishing bald cypress as a clinically significant aeroallergen in the southeastern United States. Key findings: 71% positive nasal challenges in 12 of 17 sensitized rhinitis subjects (a very high nasal provocation positivity rate); 59% RAST-positive in the sensitized cohort. The paper remains the primary clinical evidence for bald cypress allergic sensitization and is the reason Florida and Gulf Coast allergists include bald cypress in regional extract formulations.
Bald cypress (Taxodium distichum) was formerly classified in its own family Taxodiaceae, but modern molecular phylogenetics reclassified it — along with sequoia, dawn redwood, and related genera — into an expanded Cupressaceae family. Mountain cedar, eastern red cedar, Arizona cypress, Japanese cedar, and bald cypress are now all considered Cupressaceae under this broader classification. The immunologic significance of this reclassification: all share the pectate-lyase protein chemistry (Jun a 1 / Cup a 1 framework) that defines Cupressaceae cross-reactivity, which is why IgE inhibition cross-reactivity between bald cypress and red cedar was predictable and confirmed by Ramirez & Lockey 2012.
Yes — red cedar SCIT is the most evidence-supported approach for bald cypress-sensitized patients, given that IgE inhibition cross-reactivity between the two species is formally documented by Ramirez & Lockey 2012. Because bald cypress has no named allergen and no species-specific extract characterization, using red cedar extract (Jun v 1) as the Cupressaceae anchor is the standard clinical approach in the southeastern US. Your allergist may also include bald cypress directly in the extract formulation if a regional southeastern mix containing bald cypress is available from commercial suppliers. A board-certified allergist in Florida or the Gulf Coast will be familiar with this approach.
Cupressaceae SCIT for bald cypress sensitization is typically covered under standard allergy benefits when Cupressaceae sensitization is confirmed by skin test or specific IgE. Since bald cypress has no named allergen for serology, the diagnosis is typically anchored to red cedar IgE testing with bald cypress cross-reactivity documented in the clinical history. Most major US insurers cover Cupressaceae SCIT in Florida as a recognized regional indication. Out-of-pocket cost depends on your plan's deductible and co-insurance, and pre-authorization may be required.
Yes — Cupressaceae SCIT for bald cypress cross-reactive sensitization is appropriate for children typically from age 5 upward using age- and weight-adjusted dosing per the AAAAI/ACAAI Practice Parameters. In Florida, where bald cypress is a prominent December–February pediatric aeroallergen affecting school-age children during the winter semester, Florida allergists regularly prescribe Cupressaceae SCIT. Starting immunotherapy in childhood may reduce asthma risk. A pediatric allergist or pediatric immunologist can confirm Cupressaceae sensitization and design an appropriate protocol anchored to red cedar or regional southeastern cypress extract. Note: the Curex at-home pilot is currently open to patients age 12 and older; pediatric patients require a trained adult caregiver physically present for every injection. On safety, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots — supporting the safety of properly supervised at-home administration.
Bald cypress (Taxodium distichum) is a deciduous conifer — it drops its needles in fall, unlike most other cypress trees that are evergreen. It grows in standing water in wetlands, swamps, and river bottoms — its characteristic 'knees' (pneumatophores) protrude from flooded soil. Arizona cypress (Hesperocyparis arizonica) is an evergreen conifer growing in dry desert uplands, with the well-characterized Cup a 1 allergen. Mountain cedar and eastern red cedar (Juniperus spp.) are evergreen junipers — also distinct from bald cypress botanically but sharing Cupressaceae family chemistry. The key clinical difference: bald cypress lacks a named allergen and has lower pollen counts, while Arizona cypress and the junipers are better characterized molecularly.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.